Curis Lifesciences was incorporated on June 2, 2010. The company is a pharmaceutical manufacturer producing tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates through three models—loan license manufacturing for domestic clients, contract manufacturing where it manages complete production, and direct exports under its own brand in markets such as Yemen and Kenya
| Bidding Dates |
|---|
| 07 Nov 2025 - 11 Nov 2025 |
| Subscription |
|---|
| 69.25x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,40,000 | 2 | 2 | 1000 | 2.1 M | ₹120 - ₹128 | 68.03 % | ₹258.0 M - ₹275.2 M | RHP DOC |
Curis Lifesciences IPO SUBSCRIPTION STATUS
11 Nov '25Curis Lifesciences IPO overall subscription rate was 69.25 times the total available shares
Curis Lifesciences IPO retail subscription rate was 58.79 times in the retail segment
Curis Lifesciences IPO non-institutional investor subscription rate was 154.32 times in the non-institutional investor category
Curis Lifesciences IPO Qualified Institutional Bidder subscription rate was 51.05 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
11 Nov 2025 (Day 3) | 58.79x | 154.32x | 51.05x |
10 Nov 2025 (Day 2) | 4.92x | 5.86x | 4.43x |
07 Nov 2025 (Day 1) | 1.12x | 1.59x | 4.43x |
Curis Lifesciences FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 4MFY26 | 19.5 | 2.9 | 0.6 | 0.5 | 21.7% |
| FY25 | 49.1 | 6.1 | -1.8 | -1.9 | 19.4% |
| FY24 | 35.6 | 4.9 | 0.3 | 0.2 | 23.6% |
| FY23 | 35.4 | 1.9 | 3.4 | 2.8 | 9.2% |
Curis Lifesciences IPO SUBSCRIPTION STATUS DETAILS
Curis Lifesciences had 2.1 M shares on offer
Curis Lifesciences IPO offer price was in the range ₹120 - ₹128
Curis Lifesciences IPO minimum Investment was ₹240000
Curis Lifesciences IPO issue size was ₹ 258.0 M - ₹ 275.2 M
Curis Lifesciences had a minimum lot size of 1000 Shares per application
Curis Lifesciences NUMBER OF SHARES ON OFFER
Curis Lifesciences IPO IMPORTANT DATES
| Issue Open Date | 07 Nov 2025 |
| Issue close Date | 11 Nov 2025 |
| Allotment Date | 12 Nov 2025 |
| Refund Date | 13 Nov 2025 |
| Demat Account Credit Date | 13 Nov 2025 |
| Listing Date | 14 Nov 2025 |
| Listing on Exchange(s) | NSE |
| Curis Lifesciences Allotment Status | Exchange/ Registrar |
Curis Lifesciences IPO subscription opened on 07 Nov 2025, and closed on 11 Nov 2025
IPO allotment for Curis Lifesciences was finalized on Wednesday, 12 Nov 2025
IPO listing for Curis Lifesciences was on NSE on Friday, 14 Nov 2025
Curis Lifesciences IPO LISTING GAINS
| Issue Price (adjusted) | 128.0 |
| Listing Open Price | 146.1 |
| Listing Close Price | 141.0 |
| Listing Gain% | 14.1% |
| Current Gain% | -16.4% |
Curis Lifesciences Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curis Lifesciences Ltd. | 107 | 86.5 | 12.5 | 0.9 | 1.4 | 14.6 | 8.5 | 60.9 | 22.7 | 6.9 | 13.3 | 8.6 | 13.3 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Curis Lifesciences INFORMATION ON IPO ISSUE
About Curis Lifesciences
Curis Lifesciences was incorporated on June 2, 2010. The company is a pharmaceutical manufacturer producing tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates through three models—loan license manufacturing for domestic clients, contract manufacturing where it manages complete production, and direct exports under its own brand in markets such as Yemen and Kenya
Object of the Issue
- Capital expenditure towards upgradation/Improvement of its existing manufacturing facilities
- Capital expenditure towards construction of a storage facility
- Pre-payment/Repayment of outstanding secured loans
- Product registrations in other countries
- Funding their working capital requirements
- General corporate purposes
Curis Lifesciences - PROMOTERS
| Name |
|---|
| Dharmesh Dasharathbhai Patel |
| Siddhant Jayantibhai Pawasia |
| Piyush Gordhanbhai Antala |
| Jaimik Mansukhlal Patel |
Curis Lifesciences - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Dharmesh Dasharathbhai Patel | Chairman & Managing Director |
| Piyush Gordhanbhai Antala | Whole-time Director |
| Jaimik Mansukhlal Patel | Whole-time Director |
| Siddhant Jayantibhai Pawasia | Non- Executive Director |
| Chand Rameshbhai Kanabar | Independent Director |
| Grishma A Shewale | Independent Director |
| Dhruvi Shyam Kapadia | Independent Director |
Curis Lifesciences Book Running Lead Manager
Finaax Capital Advisors Private Limited
info@finaaxcapital.com
Curis Lifesciences Registrar to the issue
MUFG Intime India Private Limited
curislifesciences.smeipo@in.mpms.mufg.com
Curis Lifesciences Strengths
Scalable business model
The company follows a customer-focused, order-driven business model that emphasises efficient resource use, consistent quality, and cost-effectiveness. Its growth is driven by market expansion, product innovation, and a strong commitment to meeting customer needs through quality and marketing excellence
Quality assurance
Quality is at the core of the company's operations, aimed at ensuring excellence and long-term customer trust. Its manufacturing facility meets stringent global standards, accredited by WHO-GMP and health authorities in Yemen, Kenya, the Philippines, and Nigeria, reflecting its strong commitment to quality and regulatory compliance
Curis Lifesciences Risks
Regulatory risks
The company operates in a highly regulated industry that depends on timely approvals and renewals from health authorities. The company holds certifications from WHO-GMP, Kenya’s PPB, Yemen’s MOH, the Philippines FDA, and Nigeria’s NAFDAC. Any delay, lapse, or regulatory change affecting these approvals could impact its operations, strategy, and profitability
Non-compliance risks
The company's manufacturing facility is regularly inspected by regulatory authorities and clients to ensure compliance and quality. Any non-compliance or regulatory action could disrupt operations, delay deliveries, and harm its reputation, profitability, and financial stability. However, the company has not faced any such adverse instances to date
Safety risks
The company's manufacturing process involves hazardous and flammable chemicals, posing potential safety and compliance risks. Despite strict controls, any mishandling or system failure could lead to accidents, injuries, or environmental damage, resulting in penalties, legal action, and reputational harm, while also disrupting production and operations
IPO FAQs
The promoters of the company are Dharmesh Dasharathbhai Patel, Siddhant Jayantibhai Pawasia, Piyush Gordhanbhai Antala and Jaimik Mansukhlal Patel.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 120.0 - 128.0.
The IPO application opens on Nov 07, 2025 and closes on Nov 11, 2025.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 240,000.0, the maximum value for this IPO is Rs 256,000.0.
This IPO will be allotted on Nov 12, 2025.
The refund will be credited to your account on Nov 13, 2025.
The allotted shares will be credited to your demat on Nov 13, 2025.
Curis Lifesciences Ltd.’s shares listed on the stock exchanges on Nov 14, 2025.